CY1119599T1 - Μορια αντισωματων δεσμευσης-θρομβινης και χρησεις εξ’ αυτων - Google Patents
Μορια αντισωματων δεσμευσης-θρομβινης και χρησεις εξ’ αυτωνInfo
- Publication number
- CY1119599T1 CY1119599T1 CY20171101189T CY171101189T CY1119599T1 CY 1119599 T1 CY1119599 T1 CY 1119599T1 CY 20171101189 T CY20171101189 T CY 20171101189T CY 171101189 T CY171101189 T CY 171101189T CY 1119599 T1 CY1119599 T1 CY 1119599T1
- Authority
- CY
- Cyprus
- Prior art keywords
- thrombine
- corruption
- motors
- binding
- thrombin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1121513.4A GB201121513D0 (en) | 2011-12-14 | 2011-12-14 | Thrombin-binding antibody molecules and uses thereof |
| PCT/GB2012/053140 WO2013088164A1 (en) | 2011-12-14 | 2012-12-14 | Thrombin-binding antibody molecules and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1119599T1 true CY1119599T1 (el) | 2018-04-04 |
Family
ID=45560465
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20171101189T CY1119599T1 (el) | 2011-12-14 | 2017-11-14 | Μορια αντισωματων δεσμευσης-θρομβινης και χρησεις εξ’ αυτων |
Country Status (34)
| Country | Link |
|---|---|
| US (5) | US9518129B2 (https=) |
| EP (2) | EP2791177B1 (https=) |
| JP (2) | JP6216954B2 (https=) |
| KR (1) | KR102114506B1 (https=) |
| CN (2) | CN107936119B (https=) |
| AU (2) | AU2012351858B2 (https=) |
| BR (1) | BR112014014605A2 (https=) |
| CA (1) | CA2856656C (https=) |
| CO (1) | CO7101192A2 (https=) |
| CY (1) | CY1119599T1 (https=) |
| DK (1) | DK2791177T3 (https=) |
| ES (1) | ES2642718T3 (https=) |
| GB (1) | GB201121513D0 (https=) |
| HK (1) | HK1246326A1 (https=) |
| HR (1) | HRP20171775T1 (https=) |
| HU (1) | HUE034793T2 (https=) |
| IL (1) | IL232797B (https=) |
| LT (1) | LT2791177T (https=) |
| ME (1) | ME02901B (https=) |
| MX (2) | MX376876B (https=) |
| MY (1) | MY170980A (https=) |
| NO (1) | NO2791177T3 (https=) |
| PE (2) | PE20190171A1 (https=) |
| PH (1) | PH12014501169B1 (https=) |
| PL (1) | PL2791177T3 (https=) |
| PT (1) | PT2791177T (https=) |
| RS (1) | RS56510B1 (https=) |
| RU (2) | RU2642276C2 (https=) |
| SG (1) | SG11201402560WA (https=) |
| SI (1) | SI2791177T1 (https=) |
| SM (1) | SMT201700580T1 (https=) |
| UA (1) | UA116531C2 (https=) |
| WO (1) | WO2013088164A1 (https=) |
| ZA (1) | ZA201403836B (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201121513D0 (en) | 2011-12-14 | 2012-01-25 | Cambridge Entpr Ltd | Thrombin-binding antibody molecules and uses thereof |
| US9518128B2 (en) | 2011-12-14 | 2016-12-13 | Janssen Pharmaceuticals, Inc. | Thrombin-binding antibody molecules |
| GB201310949D0 (en) * | 2013-06-19 | 2013-07-31 | Cambridge Entpr Ltd | Binding Motif |
| GB201310948D0 (en) * | 2013-06-19 | 2013-07-31 | Cambridge Entpr Ltd | Screening methods |
| CN107043423B (zh) * | 2016-02-05 | 2021-02-26 | 江苏恒瑞医药股份有限公司 | 凝血酶抗体、其抗原结合片段及医药用途 |
| EP3412688A4 (en) * | 2016-02-05 | 2019-12-04 | Jiangsu Hengrui Medicine Co., Ltd. | THROMBIN ANTIBODY, ANTIGENBINDING FRAGMENT, AND PHARMACEUTICAL USE THEREOF |
| WO2018081534A1 (en) * | 2016-10-28 | 2018-05-03 | President And Fellows Of Harvard College | Assay for exo-site binding molecules |
| WO2019030706A1 (en) | 2017-08-10 | 2019-02-14 | Janssen Pharmaceutica Nv | ANTI-THROMBIN ANTIBODY MOLECULES AND METHODS OF USE IN ORTHOPEDIC SURGERY |
| WO2019035055A1 (en) | 2017-08-16 | 2019-02-21 | Janssen Pharmaceutica Nv | ANTI-THROMBIN ANTIBODY MOLECULES AND METHODS OF USE WITH PLATELET ANTI-AGGREGATE AGENTS |
| WO2020003077A1 (en) * | 2018-06-25 | 2020-01-02 | Janssen Pharmaceutica Nv | Anti-thrombin antibody molecules for use in patients at risk for gastrointestinal (gi) bleeding |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1989011297A1 (en) * | 1988-05-27 | 1989-11-30 | Centocor, Inc. | Freeze-dried formulation for antibody products |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5240913A (en) | 1989-08-18 | 1993-08-31 | Biogen, Inc. | Inhibitors of thrombin |
| US5196404B1 (en) | 1989-08-18 | 1996-09-10 | Biogen Inc | Inhibitors of thrombin |
| CA2082643A1 (en) | 1990-05-10 | 1991-11-11 | Jan H. Nuijens | Inhibitors of factor xii activation and applications thereof |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5443827A (en) * | 1993-05-03 | 1995-08-22 | President And Fellows Of Harvard College | Fibrin-targeted inhibitors of thrombin |
| AU1378495A (en) * | 1993-12-27 | 1995-07-17 | Hamilton Civic Hospitals Research Development, Inc. | Methods and compositions for inhibiting thrombogenesis |
| GB9613718D0 (en) | 1996-06-29 | 1996-08-28 | Thrombosis Res Inst | Thrombin inhibitors |
| US5985833A (en) | 1996-09-17 | 1999-11-16 | Wisconsin Alumni Research Foundation | Thrombin inhibitor |
| WO2001000667A2 (en) | 1999-06-29 | 2001-01-04 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-thrombin peptide from anopheles albimanus salivary gland |
| CA2378473A1 (en) * | 1999-07-23 | 2001-02-01 | The Regents Of The University Of California | Modulation of platelet activation |
| BR0015872A (pt) * | 2000-05-15 | 2004-08-03 | Smithkline Beecham Corp | Agentes antitrombóticos |
| AU2001286900A1 (en) | 2000-08-31 | 2002-03-13 | Cor Therapeutics, Inc. | Therapeutics and diagnostics based on a novel signal transduction system in platelets |
| EP1411964A4 (en) * | 2001-07-06 | 2006-06-14 | Oregon Health Science Universi | PEPTIDES MODULATING BLOOD COAGULATION AND METHODS OF USE |
| TWI338009B (en) * | 2001-10-29 | 2011-03-01 | Genentech Inc | Antibodies for inhibiting blood coagulation and methods of use thereof |
| BRPI0614961A2 (pt) | 2005-08-26 | 2016-09-13 | Archemix Corp | aptâmero, método, e, composição |
| EP2001504A2 (en) | 2006-03-15 | 2008-12-17 | Emory University | Use of thrombin mutants to inhibit the anticoagulation effect of thrombin inhibitors |
| GB0711779D0 (en) | 2007-06-18 | 2007-07-25 | Univ Singapore | Thrombin inhibitor |
| WO2009154461A1 (en) | 2008-06-19 | 2009-12-23 | Prothix Bv | Use of anti-factors xi antibodies for prevention of thrombus formation |
| US20110275701A1 (en) * | 2008-09-18 | 2011-11-10 | Archemix Corp. | Anti-thrombin aptamer formulations and methods for use |
| ES3005912T3 (en) | 2011-07-22 | 2025-03-17 | Csl Behring Gmbh | Inhibitory anti-factor xii/xiia monoclonal antibodies and their uses |
| US9518128B2 (en) * | 2011-12-14 | 2016-12-13 | Janssen Pharmaceuticals, Inc. | Thrombin-binding antibody molecules |
| GB201121513D0 (en) | 2011-12-14 | 2012-01-25 | Cambridge Entpr Ltd | Thrombin-binding antibody molecules and uses thereof |
-
2011
- 2011-12-14 GB GBGB1121513.4A patent/GB201121513D0/en not_active Ceased
-
2012
- 2012-12-14 LT LTEP12806641.2T patent/LT2791177T/lt unknown
- 2012-12-14 MX MX2018000197A patent/MX376876B/es unknown
- 2012-12-14 DK DK12806641.2T patent/DK2791177T3/en active
- 2012-12-14 KR KR1020147019168A patent/KR102114506B1/ko not_active Expired - Fee Related
- 2012-12-14 AU AU2012351858A patent/AU2012351858B2/en not_active Ceased
- 2012-12-14 US US14/363,514 patent/US9518129B2/en not_active Expired - Fee Related
- 2012-12-14 MY MYPI2014001764A patent/MY170980A/en unknown
- 2012-12-14 ME MEP-2017-243A patent/ME02901B/me unknown
- 2012-12-14 BR BR112014014605A patent/BR112014014605A2/pt not_active Application Discontinuation
- 2012-12-14 WO PCT/GB2012/053140 patent/WO2013088164A1/en not_active Ceased
- 2012-12-14 EP EP12806641.2A patent/EP2791177B1/en active Active
- 2012-12-14 RU RU2014124985A patent/RU2642276C2/ru active
- 2012-12-14 PE PE2018002007A patent/PE20190171A1/es unknown
- 2012-12-14 HU HUE12806641A patent/HUE034793T2/en unknown
- 2012-12-14 ES ES12806641.2T patent/ES2642718T3/es active Active
- 2012-12-14 SM SM20170580T patent/SMT201700580T1/it unknown
- 2012-12-14 HR HRP20171775TT patent/HRP20171775T1/hr unknown
- 2012-12-14 RU RU2017144629A patent/RU2017144629A/ru unknown
- 2012-12-14 UA UAA201406892A patent/UA116531C2/uk unknown
- 2012-12-14 EP EP17177235.3A patent/EP3275903A1/en not_active Withdrawn
- 2012-12-14 SI SI201231145T patent/SI2791177T1/en unknown
- 2012-12-14 PE PE2014000953A patent/PE20141706A1/es active IP Right Grant
- 2012-12-14 NO NO12806641A patent/NO2791177T3/no unknown
- 2012-12-14 CN CN201711384542.3A patent/CN107936119B/zh not_active Expired - Fee Related
- 2012-12-14 CA CA2856656A patent/CA2856656C/en active Active
- 2012-12-14 SG SG11201402560WA patent/SG11201402560WA/en unknown
- 2012-12-14 MX MX2014007170A patent/MX353281B/es active IP Right Grant
- 2012-12-14 RS RS20171073A patent/RS56510B1/sr unknown
- 2012-12-14 CN CN201280061294.8A patent/CN104053673B/zh not_active Expired - Fee Related
- 2012-12-14 PT PT128066412T patent/PT2791177T/pt unknown
- 2012-12-14 PL PL12806641T patent/PL2791177T3/pl unknown
- 2012-12-14 JP JP2014546649A patent/JP6216954B2/ja not_active Expired - Fee Related
-
2014
- 2014-05-26 ZA ZA2014/03836A patent/ZA201403836B/en unknown
- 2014-05-26 IL IL232797A patent/IL232797B/en active IP Right Grant
- 2014-05-26 PH PH12014501169A patent/PH12014501169B1/en unknown
- 2014-07-11 CO CO14150372A patent/CO7101192A2/es unknown
-
2016
- 2016-11-10 US US15/348,250 patent/US9988463B2/en active Active
-
2017
- 2017-08-30 JP JP2017165700A patent/JP6705785B2/ja not_active Expired - Fee Related
- 2017-11-14 CY CY20171101189T patent/CY1119599T1/el unknown
- 2017-12-01 AU AU2017268655A patent/AU2017268655B2/en not_active Ceased
-
2018
- 2018-05-08 HK HK18105913.3A patent/HK1246326A1/en unknown
- 2018-05-10 US US15/976,512 patent/US10287363B2/en not_active Expired - Fee Related
-
2019
- 2019-03-25 US US16/363,396 patent/US20190276558A1/en not_active Abandoned
-
2021
- 2021-06-10 US US17/344,577 patent/US20210371543A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1119599T1 (el) | Μορια αντισωματων δεσμευσης-θρομβινης και χρησεις εξ’ αυτων | |
| CY1122478T1 (el) | Συνθεσεις που περιεχουν anti-cd38 αντισωματα και λεναλιδομιδη | |
| CY1121517T1 (el) | Μη φουκοζυλιωμενα αντισωματα enanti-fgfr2iiib | |
| CY1121546T1 (el) | Ανθρωποποιημενα αντισωματα εναντι liv-1 και χρηση των ιδιων στην αγωγη του καρκινου | |
| CY1120471T1 (el) | Αντισωματα κατα του cd70 | |
| CY1121299T1 (el) | Υποκατεστημενες τρικυκλικες ενωσεις ως αναστολεις fgfr | |
| CY1123977T1 (el) | Anti-pd-1 και anti-lag3 αντισωματα για την θεραπεια του καρκινου | |
| CY1121862T1 (el) | Αντισωματα anti-phf-tau και χρησεις αυτων | |
| CY1119994T1 (el) | Συνθεσεις και μεθοδοι για αυξηση της μυϊκης μαζας και της μυϊκης δυναμης ανταγωνιζοντας ειδικα ton gdf8 και/ή την ακτιβινη α | |
| CY1124360T1 (el) | Αντισωματα aντι-il-33 και χρησεις αυτων | |
| EA201791485A1 (ru) | Анти-cd47-антитела и их применения | |
| CY1120729T1 (el) | Πεπτιδια και συνθεσεις για τη θεραπεια τραυματισμου των αρθρωσεων | |
| EA201691470A1 (ru) | Белки, связывающие калликреин плазмы, и их применение для лечения наследственного ангионевротического отека | |
| CY1120557T1 (el) | Μορια δεσμευσης anti-pseudomonas psl και χρησεις αυτων | |
| MX374291B (es) | Modulocinas basadas en dominio sushi de interleucina-15 (il-15) y receptor alfa de interleucina-15 (il-15ra). | |
| BR112018003269A2 (pt) | conjugados de fármaco-anticorpo anti-dll3 e métodos de utilização | |
| EA201491644A1 (ru) | Фармацевтические композиции | |
| EA201890321A1 (ru) | Молекулы антител, которые связываются с cd45 | |
| EA201690314A1 (ru) | Анти-garp-белок и его применения | |
| MX2018010295A (es) | Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos. | |
| EA202193044A2 (ru) | Способы лечения таупатии | |
| EA201791550A1 (ru) | Димеры бензодиазепинов, их конъюгаты и способы их получения и применения | |
| CY1121167T1 (el) | Βελτιωμενα αντισωματα εναντι της ανθρωπινης φρακταλκινης και χρησεις αυτων | |
| EA201890754A1 (ru) | Соединения и способы их применения | |
| EA201291065A1 (ru) | Антитела против vla-4 |